• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Vas Boston visit July 8.













But he and to meet with customers! Too bad none of our customers give a shit about him...need to pull favors and for what. Play the game I tell myself Novartis pays well...but does it?
 




















Apparently you did not not get the dinner invitation.
Apparently you have still not got a dose of Novartis. Fall on your face. This non MD equipped with only a degree but no substance to treat or understand patients. Charisma and personality are a mask for incompetence. If you like that then be the cheerleader. Good luck to you.
 




Vas has an MD, although never practiced, but has never sold a drug. Working on vaccine tenders with no reps is not the same as pharma sales (where most of our money is made). We now have no one in leadership with experience in US pharmaceutical sales. Paul was just a visiting Brit - with him gone - we have no one
 




Vas has an MD, although never practiced, but has never sold a drug. Working on vaccine tenders with no reps is not the same as pharma sales (where most of our money is made). We now have no one in leadership with experience in US pharmaceutical sales. Paul was just a visiting Brit - with him gone - we have no one
Vas has no experience in conducting proper clinics trials either. His background in NVS clinical trial (Global development) was a misfit. Instead of throwing him out, they made him CEO. Go figure. Thank all the people who did the real work. Vas and many like him are not worth a dime.
 








what a joke

So interesting that Dave Lennon won’t visit Boston Children’s as President of AveXis but new president of Novartis Pharma will

These are supposed to be independently run companies and yet Novartis can’t keep their hands out of it
 












Vas has no experience in conducting proper clinics trials either. His background in NVS clinical trial (Global development) was a misfit. Instead of throwing him out, they made him CEO. Go figure. Thank all the people who did the real work. Vas and many like him are not worth a dime.
Well, the leadership is certainly pedigreed these days. We have many ivy leaguers who can't manage their way out of a paper bag. They know how to manage things, time, money but certainly not people. Their ethereal approach is disappointing. We do not live,work,develop in a socialist society. Please quit managing our US business with a socialist attitude.